Eli Lilly and Chinese biotech specialist Innovent Biologics have received approval in China for their biosimilar rituximab, Halpryza. The companies are continuing to co-develop and commercialize other oncology medicines for the Chinese market.
China’s National Medical Products Administration has approved the Halpryza (rituximab) biosimilar co-developed by Eli Lilly and Chinese biotech specialist Innovent Biologics.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.
